Our top pick for
Building a portfolio
Westlake Chemical Partners LP is a chemicals business based in the US. Westlake Chemical Partners shares (WLKP) are listed on the NYSE and all prices are listed in US Dollars.
|52-week range||$9.39 - $24.50|
|50-day moving average||$23.53|
|200-day moving average||$21.23|
|Wall St. target price||$25.50|
|Dividend yield||$1.886 (7.71%)|
|Earnings per share (TTM)||$1.88|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Westlake Chemical Partners stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Westlake Chemical Partners's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Westlake Chemical Partners's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Westlake Chemical Partners shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Westlake Chemical Partners's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.23. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Westlake Chemical Partners's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Westlake Chemical Partners's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $456.1 million.
The EBITDA is a measure of a Westlake Chemical Partners's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$966.7 million|
|Operating margin TTM||36.52%|
|Gross profit TTM||$378.9 million|
|Return on assets TTM||16.05%|
|Return on equity TTM||36.54%|
|Market capitalisation||$862.7 million|
TTM: trailing 12 months
There are currently 214,137 Westlake Chemical Partners shares held short by investors – that's known as Westlake Chemical Partners's "short interest". This figure is 18.4% up from 180,803 last month.
There are a few different ways that this level of interest in shorting Westlake Chemical Partners shares can be evaluated.
Westlake Chemical Partners's "short interest ratio" (SIR) is the quantity of Westlake Chemical Partners shares currently shorted divided by the average quantity of Westlake Chemical Partners shares traded daily (recently around 176972.72727273). Westlake Chemical Partners's SIR currently stands at 1.21. In other words for every 100,000 Westlake Chemical Partners shares traded daily on the market, roughly 1210 shares are currently held short.
However Westlake Chemical Partners's short interest can also be evaluated against the total number of Westlake Chemical Partners shares, or, against the total number of tradable Westlake Chemical Partners shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Westlake Chemical Partners's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Westlake Chemical Partners shares in existence, roughly 10 shares are currently held short) or 0.017% of the tradable shares (for every 100,000 tradable Westlake Chemical Partners shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Westlake Chemical Partners.
Find out more about how you can short Westlake Chemical Partners stock.
Dividend payout ratio: 99.77% of net profits
Recently Westlake Chemical Partners has paid out, on average, around 99.77% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 7.71% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Westlake Chemical Partners shareholders could enjoy a 7.71% return on their shares, in the form of dividend payments. In Westlake Chemical Partners's case, that would currently equate to about $1.886 per share.
Westlake Chemical Partners's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Westlake Chemical Partners's most recent dividend payout was on 18 February 2021. The latest dividend was paid out to all shareholders who bought their shares by 2 February 2021 (the "ex-dividend date").
Over the last 12 months, Westlake Chemical Partners's shares have ranged in value from as little as $9.3889 up to $24.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Westlake Chemical Partners's is 1.1923. This would suggest that Westlake Chemical Partners's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Westlake Chemical Partners LP acquires, develops, and operates ethylene production facilities and related assets in the United States. The company's ethylene production facilities primarily convert ethane into ethylene. It also sells ethylene co-products, including propylene, crude butadiene, pyrolysis gasoline, and hydrogen directly to third parties on a spot or contract basis. Westlake Chemical Partners GP LLC serves as the general partner of the company. The company was founded in 2014 and is headquartered in Houston, Texas. .
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.